Neupogen (filgrastim) Market Outlook 2025-2034: Key Trends, Growth Drivers, and Market Share

How Big Is the Neupogen (filgrastim) Market Expected to Be, and What Will Its Growth Rate Be?
In the recent past, the market size of neupogen (filgrastim) has seen a significant surge. The sector is expected to boost from $1,330.69 million in 2024, reaching up to $1,404.70 billion in 2025 with a compound annual growth rate (CAGR) of 5.6%. Factors such as a surge in cancer cases, increased understanding of chemotherapy-induced neutropenia, enhancements in healthcare infrastructure, early green lights for Neupogen biosimilars, and a rise in global healthcare expenditure have contributed to the growth observed in the historical period.

There is a predicted robust growth in the neupogen (filgrastim) market over the coming years, expanding to a total value of $1,727.05 million in 2029 at a compound annual growth rate (CAGR) of 5.3%. This growth trajectory in the projected period can be linked to increasing requirements for affordable neutropenia treatment, the broadening of healthcare coverage in growing markets, elevated governmental backing for biosimilar penetration, an enhanced emphasis on personalized healthcare, and an aging global population. Noteworthy trends during this forecast period include escalated investment in biosimilars research and development, advancements in neutropenia treatment drug delivery systems, expanding alliances for the commercial distribution of oncology drugs, a reinforced commitment to patient affordability programs, and the creation of next-generation G-CSF products.

What Are the Primary Growth Drivers for the Neupogen (filgrastim) Market?
The growth of the neupogen (filgrastim) market is projected to be fueled by a rising prevalence of various diseases. These diseases, which may be caused by factors including infections, genetics, environmental factors, or lifestyle choices, interfere with the body's structure or functioning, causing particular symptoms or affecting specified locations. An increase in diseases is being pushed by elements such as an aging population, inactive lifestyles, rising pollution levels, unhealthy dietary habits, and the worldwide distribution of infectious diseases. Neupogen (filgrastim) helps alleviate chemotherapy-induced neutropenia complications by promoting neutrophil production, thereby augmenting the ability of the immune system to fight off infections in those with compromised immunity. Markedly, it reduces hospitalization rates, manages infection risks, and enables continuous cancer treatment for patients undergoing intense therapies. For instance, Allergy UK reported in April 2024 that allergies, the most often reported chronic health condition in 2022, impacted more than 21 million people in the UK. Additionally, Macmillan Cancer Support data from June 2022 indicated that there were 3 million people living with cancer in 2022, a figure projected to increase to nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Hence, the rise in various diseases' prevalence is driving the growth of the neupogen (filgrastim) market. The growth of the neupogen (filgrastim) market is also expected to be advanced by government-led healthcare research and development initiatives. Government actions, whether at a local, regional, national, or international level, can benefit society, resolve particular issues, or help achieve certain objectives. Several government authorities are setting up numerous healthcare initiatives to support facets including neupogen (filgrastim). The Department of Health and Social Care, for example, disclosed in 2022 that the UK government had committed £260 million (US $270.65 million) to boost healthcare research and manufacturing. The monies were earmarked by BEIS and DHSC to support NHS-led health research into diagnostics and treatments via new privacy-preserving platforms and clinical research services, and to provide £60 million (US $63.60 million) to expand life sciences manufacturing in the UK. Therefore, government-led healthcare R&D initiatives are stimulating the neupogen (filgrastim) market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp

Who Are the Dominant Companies Influencing Neupogen (filgrastim) Market Trends?
Major companies operating in the neupogen (filgrastim) market include Amgen Inc.

How Is the Neupogen (filgrastim) Market Evolving?
One dominant trend within the neupogen (filgrastim) market is the emphasis on pioneering novel products, particularly filgrastim biosimilar solutions. These are designed to serve as a cost-effective and accessible alternative for managing chemotherapy-induced neutropenia. These biosimilar solutions are biological medications that replicate the original filgrastim (Neupogen), ensuring safety, efficacy, and structure primarily to encourage the production of neutrophils in chemotherapy patients, hence preventing neutropenia. For example, in November 2022, Amneal Pharmaceuticals and Kashiv Biosciences, both US-based companies operating in the pharmaceutical and biopharmaceutical sectors respectively, introduced a biosimilar referencing Neupogen (filgrastim) called Releuko (filgrastim-ayow), into the US market. Releuko, which comes in intravenous and subcutaneous formulations, is available in single-dose vials and prefilled syringes, providing dosage flexibility for healthcare providers. It holds significance as it offers an affordable treatment alternative for chemotherapy-induced neutropenia, enhances the availability of vital oncology care, and caters to the growing demand for biosimilars in the market.

What Are the Different Segmentations in the Neupogen (filgrastim) Market?
The neupogen (filgrastim)market covered in this report is segmented -

1) By Drug Type: Biologic; Biosimilar
2) By Indication: Chemotherapy Induced Neutropenia; Chronic Neutropenia; Others
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

Which Region Is at the Forefront of the Neupogen (filgrastim) Market?
North America was the largest region in the neupogen (filgrastim) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Neupogen (filgrastim) Global Market Report?

- Market Size Analysis: Analyze the neupogen (filgrastim) Market Size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the neupogen (filgrastim) market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall neupogen (filgrastim) market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the neupogen (filgrastim) market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19910

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.